Hosseini I, Fleisher B, Getz J, Decalf J, Kwong M, Ovacik M
Pharmaceutics. 2024; 16(5).
PMID: 38794321
PMC: 11125320.
DOI: 10.3390/pharmaceutics16050660.
Niazi S
Drug Des Devel Ther. 2023; 17:2691-2725.
PMID: 37701048
PMC: 10493153.
DOI: 10.2147/DDDT.S424991.
Vora L, Gholap A, Jetha K, Thakur R, Solanki H, Chavda V
Pharmaceutics. 2023; 15(7).
PMID: 37514102
PMC: 10385763.
DOI: 10.3390/pharmaceutics15071916.
Fan X, Krzyzanski W, Liu D, Wong R, Yan X
Pharmaceutics. 2023; 15(2).
PMID: 36839666
PMC: 9962863.
DOI: 10.3390/pharmaceutics15020344.
Han S, Yim H, Jeong H, Choi S, Han S
Int J Stem Cells. 2022; 16(1):16-26.
PMID: 36581365
PMC: 9978837.
DOI: 10.15283/ijsc21189.
Growth-rate model predicts in vivo tumor response from in vitro data.
Diegmiller R, Salphati L, Alicke B, Wilson T, Stout T, Hafner M
CPT Pharmacometrics Syst Pharmacol. 2022; 11(9):1183-1193.
PMID: 35731938
PMC: 9469692.
DOI: 10.1002/psp4.12836.
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.
Germovsek E, Cheng M, Giragossian C
MAbs. 2021; 13(1):1964935.
PMID: 34530672
PMC: 8463036.
DOI: 10.1080/19420862.2021.1964935.
iPSCs: A Preclinical Drug Research Tool for Neurological Disorders.
Bonaventura G, Iemmolo R, Attaguile G, La Cognata V, Pistone B, Raudino G
Int J Mol Sci. 2021; 22(9).
PMID: 33925625
PMC: 8123805.
DOI: 10.3390/ijms22094596.
In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B, Lezeau J, Werkman C, Jacobs B, Ait-Oudhia S
Breast Cancer (Dove Med Press). 2021; 13:87-105.
PMID: 33628047
PMC: 7899308.
DOI: 10.2147/BCTT.S292161.
Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges.
Zou H, Banerjee P, Leung S, Yan X
Front Pharmacol. 2020; 11:997.
PMID: 32719604
PMC: 7348046.
DOI: 10.3389/fphar.2020.00997.
Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
Ayyar V, Jusko W
Pharmacol Rev. 2020; 72(2):414-438.
PMID: 32123034
PMC: 7058984.
DOI: 10.1124/pr.119.018101.
Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500.
Bonifacio L, Dodds M, Prohaska D, Moss A, Giaccia A, Tabibiazar R
Clin Transl Sci. 2019; 13(1):204-211.
PMID: 31599479
PMC: 6951457.
DOI: 10.1111/cts.12706.
Convergence of Cell Pharmacology and Drug Delivery.
Aijaz A, Vaninov N, Allen A, Barcia R, Parekkadan B
Stem Cells Transl Med. 2019; 8(9):874-879.
PMID: 31091020
PMC: 6708059.
DOI: 10.1002/sctm.19-0019.
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents.
Cardilin T, Almquist J, Jirstrand M, Zimmermann A, Lignet F, El Bawab S
Cancer Chemother Pharmacol. 2019; 83(6):1159-1173.
PMID: 30976845
PMC: 6499765.
DOI: 10.1007/s00280-019-03829-y.
Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics.
Suh M, Lee D
Nucl Med Mol Imaging. 2018; 52(6):407-419.
PMID: 30538772
PMC: 6261865.
DOI: 10.1007/s13139-018-0550-9.
Avibactam Pharmacokinetic/Pharmacodynamic Targets.
Nichols W, Newell P, Critchley I, Riccobene T, Das S
Antimicrob Agents Chemother. 2018; 62(6).
PMID: 29610208
PMC: 5971577.
DOI: 10.1128/AAC.02446-17.
Modeling of prolactin response following dopamine D receptor antagonists in rats: can it be translated to clinical dosing?.
Taneja A, Vermeulen A, Huntjens D, Danhof M, de Lange E, Proost J
Pharmacol Res Perspect. 2017; 5(6).
PMID: 29226628
PMC: 5723698.
DOI: 10.1002/prp2.364.
Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human.
Yang F, Wang B, Liu Z, Xia X, Wang W, Yin D
Front Pharmacol. 2017; 8:683.
PMID: 29066968
PMC: 5641330.
DOI: 10.3389/fphar.2017.00683.
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Tate S, Sykes A, Kulanthaivel P, Chan E, Turner P, Cronier D
Clin Pharmacokinet. 2017; 57(3):335-344.
PMID: 28540640
PMC: 5814509.
DOI: 10.1007/s40262-017-0559-8.
Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.
Collins T, Hattersley M, Yates J, Clark E, Mondal M, Mettetal J
CPT Pharmacometrics Syst Pharmacol. 2017; 6(6):357-364.
PMID: 28378926
PMC: 5488126.
DOI: 10.1002/psp4.12194.